The Evolving Landscape of Prostate Cancer Care
Author:
Dlamini Zodwa,Hull Rodney,Luvhengo Thifheli,Gaston Kevin
Publisher
Springer Nature Switzerland
Reference92 articles.
1. Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., Carbone, E., Barnett, E. S., Hullings, M., Hechtman, J. F., Zehir, A., Shia, J., Jonsson, P., Stadler, Z. K., Srinivasan, P., Laudone, V. P., Reuter, V., Wolchok, J. D., Socci, N. D., Taylor, B. S., Berger, M. F., Kantoff, P. W., Sawyers, C. L., Schultz, N., Solit, D. B., Gopalan, A., & Scher, H. I. (2019). Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncology, 5, 471–478. 2. Adhyam, M., & Gupta, A. K. (2012). A review on the clinical utility of PSA in cancer prostate. Indian Journal of Surgical Oncology, 3, 120–129. 3. Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., Lloyd, P., Gleave, M., Evans, C. P., Youngren, J., Beer, T. M., Rettig, M., Wong, C. K., True, L., Foye, A., Playdle, D., Ryan, C. J., Lara, P., Chi, K. N., Uzunangelov, V., Sokolov, A., Newton, Y., Beltran, H., Demichelis, F., Rubin, M. A., Stuart, J. M., & Small, E. J. (2018). Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study. Journal of Clinical Oncology, 36, 2492–2503. 4. Albright, F., Stephenson, R. A., Agarwal, N., Teerlink, C. C., Lowrance, W. T., Farnham, J. M., & Albright, L. A. (2015). Prostate cancer risk prediction based on complete prostate cancer family history. Prostate, 75, 390–398. 5. Alford, A. V., Brito, J. M., Yadav, K. K., Yadav, S. S., Tewari, A. K., & Renzulli, J. (2017). The use of biomarkers in prostate cancer screening and treatment. Revista de Urología, 19, 221–234.
|
|